Israeli alpha-radiation cancer therapy developer starts clinical trials in Italy

| By | Medical Devices, Radiopharmaceuticals

Alpha Tau Medical (Israel), developer of a breakthrough alpha-radiation cancer therapy, has announced the initiation of two new clinical trials evaluating the efficacy of the Alpha DaRT (Dіffusіng Alpha-emitters Radіatіon Therapy) with two leading medical centers in Rome (Italy).

Alpha DaRT enables the first alpha-radiation-based cancer treatment for all types of solid tumors. The team hopes that the study’s outcome will further reinforce the promising early results from the ongoing study of squamous cell carcinoma (SCC) at the Rabin Medical Center (Israel) and the IRST (Italy). Results showed all patients’ tumor sizes reduced and more than 70% of patients’ tumors completely disappeared within a few weeks after treatment.

The company is collaborating with key cancer physicians worldwide to investigate the Alpha DaRT as a treatment for additional indications including: pancreas, breast, GYN, prostate

Founded in 2016, Alpha Tau Medical, is an Israeli medical device company that focuses on research, development and commercialization of the Alpha DaRT. The treatment delivers high-precision alpha radiation, that is released when radioactive substances decay inside the tumor. The short-range alpha particles effectively kill the cancer cells while sparing the surrounding healthy tissue.

SOURCE: alpha tau medical
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.